Inhibitory effect of live-attenuated Listeria Monocytogenes-based vaccines expressing MIA gene on malignant melanoma

Abstract

Listeria monocytogenes (LM), a Gram-positive facultative intracellular bacterium, can be used as an effective exogenous antigen expression vector in tumor-target therapy. But for successful clinical application, it is necessary to construct attenuated LM stain that is safe yet retains the potency of LM based on the full virulent pathogen. In this study, attenuated LM and recombinants of LM expressing melanoma inhibitory activity (MIA) were constructed successfully. The median lethal dose (LD₅₀) and invasion efficiency of attenuated LM strains were detected. The recombinants were utilized for immunotherapy of animal model of B16F10 melanoma. The level of MIA mRNA expression in tumor tissue was detected by using real-time polymerase chain reaction (PCR) with specific sequence, meanwhile the anti-tumor immune response was assayed by flow cytometric analysis and enzyme-linked immunosorbent spot (ELISPOT) assay. The results showed the toxicity and invasiveness of attenuated LM were decreased as compared with LM, and attenuated LM expressing MIA, especially the double-genes attenuated LM recombinant, could significantly induce anti-tumor immune response and inhibit tumor growth. This study implicates attenuated LM may be a safer and more effective vector for immunotherapy of melanoma.

Keywords

Listeria monocytogenes / melanoma inhibitory activity / melanoma / vaccine, attenuated

References

[1] HussainS.F., PatersonY.. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother, 2005, 54(6): 577-586

[2] LinC.W., LeeJ.Y., TsaoY.P., et al.. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer, 2002, 102(6): 629-637

[3] FriedmanR.S., FrankelF.R., XuZ., et al.. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Virol, 2000, 74(21): 9987-9993

[4] PanZ.K., WeiskirchL.M., PatersonY.. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res, 1999, 59(20): 5264-5269

[5] PatersonY., GuirnaldaP.D., WoodL.M.. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol, 2010, 22(3): 183-189

[6] FloT.H., HalaasO., LienE., et al.. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol, 2000, 164(4): 2064-2069

[7] FengH., ZhangD., PalliserD., et al.. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J Immunol, 2005, 175(1): 421-432

[8] WayS.S., Havenar-DaughtonC., KolumamG.A., et al.. IL-12 and type-I IFN synergize for IFN-gamma production by CD4 T cells, whereas neither are required for IFN-gamma production by CD8 T cells after Listeria monocytogenes infection. J Immunol, 2007, 178(7): 4498-4505

[9] YinX.J., SchaferR., MaJ.Y., et al.. Alteration of pulmonary immunity to Listeria monocytogenes by diesel exhaust particles (DEPs). I. Effects of DEPs on early pulmonary responses. Environ Health Perspect, 2002, 110(11): 1105-1111

[10] BergmannB., RaffelsbauerD., KuhnM., et al.. InlA-but not InlB-mediated internalization of Listeria monocy togenes by non-phagocytic mammalian cells needs the support of other internalins. Mol Microbiol, 2002, 43(3): 557-570

[11] CossartP., Pizarro-CerdáJ., LecuitM.. Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions. Trends Cell Biol, 2003, 13(1): 23-31

[12] StarksH., BruhnK.W., ShenH., et al.. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J Immunol, 2004, 173(1): 420-427

[13] HaradaM., YamadaH., TatsugamiK., et al.. Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity. Immunology, 2001, 104(1): 67-74

[14] KammertoensT., SchülerT., BlankensteinT.. Immuno therapy: target the stroma to hit the tumor. Trends Mol Med, 2005, 11(5): 225-231

[15] ShankerA., SayersT.. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol, 2007, 601: 163-171

[16] GotoY., MatsuzakiY., KuriharaS., et al.. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res, 2006, 66(8): 4443-4449

[17] LugovićL., SitumM., KosL.. Malignant melanoma-future prospects. Acta Dermatovenerol Croat, 2005, 13(1): 36-43

[18] LiauL.M., JensenE.R., KremenT.J., et al.. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res, 2002, 62(8): 2287-2293

[19] MandalM., KawamuraK.S., WherryE.J., et al.. Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm, 2004, 1(1): 2-8

[20] KwakH., MustafaW., SpeirsK., et al.. Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion. Virology, 2004, 322(2): 337-348

[21] KronfeldK., AbkenH., SeligerB.. B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int J Cancer, 2005, 117(5): 794-799

[22] LeeJ.S., KimJ.W., ChoiC.H., et al.. Anti-tumor activity of Acinetobacter baumannii outer membrane protein A on dendritic cell-based immunotherapy against murine melanoma. J Microbiol, 2008, 46(2): 221-227

[23] MahnkeK., SchönfeldK., FondelS., et al.. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer, 2007, 120(12): 2723-2733

[24] ImaiH., SaioM., NonakaK., et al.. Depletion of CD4⁺CD25⁺ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci, 2007, 98(3): 416-423

[25] CoolsN., PonsaertsP., LenjouM., et al.. Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. Mol Cancer, 2006, 5: 49